logo-loader
viewEndologix Inc

Endologix stock extends rally after reporting sterling 3Q revenue and raised guidance

A preliminary report showed higher third-quarter revenue

heart image
Endologix develops and manufactures minimally invasive treatments for aortic disorders

Shares of Endologix Inc (NASDAQ:ELGX) rose on Wednesday after releasing a preliminary report which showed higher third-quarter revenue and improved revenue guidance for the year.

The company said unaudited third-quarter revenue ranged from $34.3 million to $34.7 million, higher than expectations it would hover between $29.5-$33.6 million. It guided for higher 2018 revenue of between $150-$155 million, compared with the previous range of $145-$155 million.

The shares climbed 19.8% to $2.06 in the premarket, having risen in after-hours trading on Tuesday as well.

READ: Amarin shares soar after fish oil tablet pares back risks of heart disease in trial

Oppenheimer Equity Research analyst Steven Lichtman said in a note to clients the company outlined plans to return to top-line growth in the second half of 2019.

"As part of this transformation, ELGX has completed its planned restructuring in the US which saw a reduction in sales force, and realignment of resources with an emphasis on high-volume accounts," he said.

The company's focus is on endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA).

AAA leads to a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement.

Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture, a company statement said. The overall patient mortality rate for a ruptured AAA is approximately 80%, making it a leading cause of death in the United States.

Endologix develops and manufactures minimally invasive treatments for aortic disorders. The company is based in Irvine, California.

Quick facts: Endologix Inc

Price: 1.55 USD

NASDAQ:ELGX
Market: NASDAQ
Market Cap: $27.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: LexaGene working hard to manufacture genetic analyzer that...

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) CEO Jack Regan tells Proactive the biotechnology company is working as hard as it can to get its diagnostic instrument that can be configured to detect threats like Coronavirus, into the hands of people who need it. Regan also explained the...

15 hours, 43 minutes ago

2 min read